Role of delayed salvage bevacizumab at symptomatic progression of chemorefractory glioblastoma
| Autor: | Matthew Wong, Linxin Guo, Helen Wheeler, Dasantha Jayamanne, Moire Cuncannon, Michael Back, Nicola Cove |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Oncology Male Cancer Research medicine.medical_specialty Bevacizumab Survival lcsh:RC254-282 Time-to-Treatment 03 medical and health sciences 0302 clinical medicine Refractory Surgical oncology Internal medicine Genetics medicine Clinical endpoint Humans Prospective Studies Salvage Therapy business.industry Brain Neoplasms RELAPSED DISEASE Hospital based medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Survival Analysis 030104 developmental biology Treatment Outcome 030220 oncology & carcinogenesis Disease Progression Salvage Female business Glioblastoma Median survival medicine.drug Research Article |
| Zdroj: | BMC Cancer BMC Cancer, Vol 19, Iss 1, Pp 1-8 (2019) |
| ISSN: | 1471-2407 |
| Popis: | Background Assess benefit of salvage bevacizumab (BEV) at time of symptomatic progression in patients with refractory glioblastoma (GBM). Methods Patients managed with adjuvant long course chemo-radiation therapy for GBM were entered into a prospective database. At chemorefractory symptomatic progression, patients were offered BEV or best supportive care. Re-irradiation (ReRT) was used with BEV in selected patients. BEV continued indefinitely until deterioration limited hospital based infusion. The primary endpoint was median survival calculated from date of decision for BEV to proceed (BEVstart), or decision to decline BEV (BEVreject). Results Fifty-five patients were managed of which 48 patients have relapsed disease. The median survival post relapse was 6 months (95%CI: 4.6–7.4). At relapse, 28 patients received BEV with only 14% delivered at first relapse. The median number of BEV cycles was 8 (range 1–25). ReRT was subsequently used in 16 (33%) relapsed patients. BEV treated patients were associated with improved median survival post relapse with 9 months vs 3 months (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink